कंपनी का अवलोकन
Alpha Teknova, Inc. (TKNO) operates as a specialized entity within the Healthcare sector, specifically functioning as a Drug Manufacturer focused on Specialty & Generic products. The firm's core business involves the production of critical reagents essential for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics both in the United States and internationally. Its primary product portfolio includes pre-poured media plates designed for cell growth and cloning, alongside liquid microwell plates and other related reagents. In terms of scale, the company holds a market capitalization of $151.65M and reports a trailing twelve-month revenue of $40.52M while employing 158 individuals. These valuation and revenue figures indicate that Alpha Teknova maintains a small-cap market presence typical of early-stage biotechnology firms, where capital intensity is high and revenue generation is often driven by R&D milestones rather than mature commercial sales.
वित्तीय स्वास्थ्य
The company reported a revenue of $40.52M over the trailing twelve months, yet it simultaneously recorded a net income of $-17,259,000 and an EBITDA of $-10,134,000. The substantial gap between the positive revenue of $40.52M and the negative net income reveals a cost structure characterized by high operating expenses, likely driven by research and development costs or commercialization efforts that exceed current gross profits. Free cash flow stands at $-2,396,250, which signifies that the company is currently burning cash to fund its operations and growth initiatives, thereby limiting its immediate financial flexibility without external capital raises. Margin analysis shows a Gross Margin of 33.2%, indicating that the company retains roughly one-third of its revenue after direct production costs, while the Operating Margin of -41.2% and Profit Margin of -42.6% reflect significant overhead burdens relative to sales. On the balance sheet, the company holds $21.34M in cash against $28.27M in debt, resulting in a Debt to Equity ratio of 41.10, which suggests a leveraged capital structure where debt obligations are more than four times the equity base. However, the Current Ratio of 4.58 indicates strong short-term liquidity, as the company possesses more than four times the current assets required to meet its short-term liabilities. Furthermore, the Return on Equity of -22.8% and Return on Assets of -9.3% demonstrate that management is currently generating negative returns on both shareholder capital and total assets, a common characteristic for biotech firms in development phases.
मूल्यांकन आकलन
Valuation metrics for Alpha Teknova present a complex picture due to its lack of profitability; the P/E Ratio (TTM) is listed as N/A, while the Forward P/E is -7.26, implying that the market expects earnings to remain negative or that the current forward earnings estimate does not yet turn positive. The Price to Book ratio is 2.20, suggesting that the market values the company at more than double its book value, which often reflects expectations of future asset appreciation or intangible value beyond current financial statements. Alternative metrics such as the Price to Sales ratio of 3.74 and an EV/EBITDA of -15.65 are used to value the firm since traditional earnings-based multiples are not applicable, highlighting that the company is priced based on revenue generation potential rather than current profit generation. Regarding price history, the 52-Week High is $7.48 and the 52-Week Low is $1.91; without a specific current price provided in the facts, the relative trading position cannot be calculated, but the wide range of $5.57 demonstrates significant price volatility over the past year. The Beta of 0.33 indicates that the stock's price volatility is substantially lower than the broader market, moving with only about one-third of the market's intensity, which offers a different risk profile for portfolios seeking lower correlation with general market swings.
Growth & Income
Revenue growth year-over-year stands at 7.8%, whereas Earnings Growth is N/A due to the company's current losses. The disparity between positive revenue growth and the inability to calculate earnings growth implies that while top-line sales are expanding, the bottom line has not yet achieved profitability, a standard trajectory for capital-intensive pharmaceutical manufacturing. As a non-dividend payer with a Dividend Yield of N/A and a Payout Ratio of 0.0%, the company does not distribute income to shareholders but instead retains all earnings to fund research, development, and operational expansion. This reinvestment strategy is typical for the specialty drug manufacturing industry, where sustaining growth requires continuous funding for novel therapies and diagnostic tools rather than returning capital to investors. Overall, the growth and income profile of Alpha Teknova is defined by revenue expansion coupled with a complete absence of current profitability or dividend income, relying entirely on market valuation premiums to sustain operations.